Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Tunis Med ; 102(3): 146-150, 2024 Mar 05.
Artigo em Francês | MEDLINE | ID: mdl-38545709

RESUMO

INTRODUCTION: In recent years, there has been a considerable increase in the prevalence of bacteria increasingly resistant to multiple families of antibiotics, which constitutes a major problem for public health. AIM: To determine the prevalence and different risk factors for the acquisition of multi-resistant bacteria. METHODS: This is an analytical and prospective study including patients hospitalized in the Batna University Hospital during the period from January 2023 to March 2023 presenting a documented infection with isolation of sensitive or multi-resistant strains. An operating sheet based on the different risk factors for acquiring multi-resistant bacteria has been established. RESULTS: We collected 250 patients. There are 160 men and 90 women with an average age of 44 years. Of all the strains that were identified, 100 isolates were multi-resistant bacteria. ESBL-producing Enterobacteriaceae are the most frequently isolated multi-resistant bacteria. Multivariate logistic regression analysis identified four risk factors that are significantly related to the risk of acquiring multi-resistant bacteria infection: prior antibiotic therapy [P = 0,029], use of invasive medical care [P = 0,024], the nosocomial origin of the infection [P = 0,036] and the use of public toilets [P = 0,015]. CONCLUSION: Our results clearly demonstrate that the inappropriate use of antibiotics, especially broad-spectrum antibiotics, and hand-held cross-transmission play a major role in the spread of multi-resistant bacteria in our hospital.


Assuntos
Infecção Hospitalar , Infecções por Enterobacteriaceae , Masculino , Humanos , Feminino , Adulto , Estudos Prospectivos , Infecção Hospitalar/microbiologia , Fatores de Risco , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Hospitais Universitários , Testes de Sensibilidade Microbiana , beta-Lactamases , Infecções por Enterobacteriaceae/epidemiologia , Infecções por Enterobacteriaceae/microbiologia , Farmacorresistência Bacteriana Múltipla
2.
ARP Rheumatol ; 3(Apr-Jun): 101-105, 2024 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-38368538

RESUMO

BACKGROUND: Intra-articular glucocorticoid injection (IAGI) is widely used for treatment of knee osteoarthritis (OA) flares. Response rates are generally around 70%. Several studies have tried to identify predictors of good response, but response to ultrasound (US)-guided injection has not yet been investigated. This study aimed to identify the predictors of response to IAGI performed under US guidance in patients with primary knee OA. MATERIALS AND METHODS: A total of 116 patients (116 knees) presenting with unilateral or bilateral primary knee OA were enrolled for this prospective single-center study. All were aged >40 years and met the American College of Rheumatology (ACR) criteria for knee OA. Demographic, clinical, laboratory, and imaging data were collected, injection was performed using US guidance, and tolerance was assessed. The primary efficacy endpoint was ≥40% reduction in total WOMAC score (WOMAC40). Univariate and multivariate logistic regression analyses were conducted to identify the predictors of response. RESULTS: The mean age of the patients was 64.2 ± 9.4 years and mean BMI was 29.9 ± 3.8 kg/m2. Total WOMAC40 response rate was 61.2%. In multivariate analysis, the independent predictors of response were BMI.


Assuntos
Glucocorticoides , Osteoartrite do Joelho , Ultrassonografia de Intervenção , Humanos , Osteoartrite do Joelho/tratamento farmacológico , Osteoartrite do Joelho/diagnóstico por imagem , Injeções Intra-Articulares/métodos , Masculino , Feminino , Pessoa de Meia-Idade , Estudos Prospectivos , Glucocorticoides/administração & dosagem , Glucocorticoides/uso terapêutico , Idoso , Resultado do Tratamento , Ultrassonografia de Intervenção/métodos
3.
Med Hypotheses ; 142: 109826, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32416415

RESUMO

The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19.


Assuntos
Infecções por Coronavirus/tratamento farmacológico , Etoposídeo/uso terapêutico , Pneumonia Viral/tratamento farmacológico , Betacoronavirus , COVID-19 , Dexametasona/administração & dosagem , Infecções por Vírus Epstein-Barr/complicações , Humanos , Influenza Humana/complicações , Linfo-Histiocitose Hemofagocítica/complicações , Modelos Teóricos , Pandemias , Síndrome do Desconforto Respiratório/complicações , SARS-CoV-2 , Tratamento Farmacológico da COVID-19
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA